Article Text

PDF
GW24-e3948 Evaluation of Tolvaptan in the treatment of hyponatremia in chronic heart failure patient
  1. Yang Ping
  1. Jilin University Sino-Japanese Friendship Hospital

Abstract

Objectives To evaluate the efficacy and safety of tolvaptan in the treatment of hyponatremia in patients with chronic heart failure.

Methods Screening enrolled 16 patients with chronic heart failure (≥18y), and they were randomly divided into 2 group, control group (8 cases) and treatment group (8 cases). We collected the relevant history, biochemical indicators, weight, height, general vital signs (blood pressure, heart rate and body temperature), 24-hour urine volume, heart function, rating, and Minnesota quality of life score. Serum sodium after 8 h, Serum sodium, urine volume and weight after 1d and Minnesota quality of life score after 8d, therapeutic efficacy and safety of 2 groups were evaluated.

Results The increase of serum sodium after 8 h and 1d of the treatment group was significantly higher than control group (P = 0.001). There is no difference of the increase of urine volume and the decrease of weight between 2 groups (P > 0.05), but the urine volume of treatment group has an increasing after 1d (P = 0.01), There is no difference of Minnesota quality of life score after 8d between 2 groups (P > 0.05), but the score of 2 group had significant improvements after 8d (P = 0.001). No adverse events, 1 cases of treatment group got dry mouth.

Conclusions Tolvaptan is efficacy, safety and tolerability to be used to treat Chronic heart failure patients with hyponatremia.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.